Licocoumarone
Licocoumarone is an active component derived from licorice. Licocoumarone has an IC50 of 12.56 μM and a Kd of 14.90 μM against human DYRK1A. Licocoumarone inhibits NF-κB activation by blocking IκBα degradation and p65 phosphorylation, interferes with MAPK activation via inhibiting phosphorylation, and downregulates the expression of iNOS. Licocoumarone inhibits LPS-induced expression of IL-1β, IL-6 and IL-10; it induces apoptosis of pancreatic cancer cells apoptosis and acts as a neuraminidase inhibitor (IC50 = 27.8 μM). Licocoumarone exhibits anti-inflammatory and antimicrobial activities, with antibacterial activity against Listeria and antifungal activity against Candida parapsilosis. Licocoumarone can be used in studies related to immune and inflammatory diseases, pancreatic cancer, and specific bacterial and fungal infections.
For research use only. We do not sell to patients.
- CAS No.: 118524-14-4
- Formula: C20H20O5
- Molecular Weight:340.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
DYRK1A 12.56 μM (IC50) |
DYRK1A 14.9 μM (Kd) |
IL-6 |
IL-1β |
IL-10 |
iNOS |
I-kappaBalpha |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| RAW264.7 | IC50 |
8.5 μM
Compound: 47
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
|
[PMID: 26841168] |
| SW480 | IC50 |
5.1 μM
Compound: 47
|
Inhibition of NFkappaB transcription in human SW480 cells at by luciferase reporter gene assay
Inhibition of NFkappaB transcription in human SW480 cells at by luciferase reporter gene assay
|
[PMID: 26841168] |
In Vitro
Licocoumarone (LC) (1.5-100 μM; 24 h) exhibits only extremely low cytotoxicity against RAW 264.7 macrophages even at concentrations as high as 100 μM[1].
Licocoumarone (compound 5) potently inhibits the enzymatic activity of purified human recombinant DYRK1A, with an IC50 of 12.56 μM and a Kd value of 14.90 μM; it protects purified human recombinant DYRK1A protein from pronase-induced proteolysis[2].
Licocoumarone (1.5-50 μM; 1 h pretreatment followed by 24 h LPS stimulation) dose-dependently inhibits LPS-induced NO production in RAW 264.7 macrophages[1].
Licocoumarone inhibits LPS-induced NF-κB activation in RAW 264.7 macrophages by reducing the phosphorylation level of p65 and suppressing IκBα degradation; it also inhibits TNF-α-induced NF-κB transcriptional activity in HeLa cells in a dose-dependent manner[1].
Licocoumarone (3-50 μM; pretreated for 1 hour followed by LPS stimulation for 30 minutes) dose-dependently inhibits LPS-induced phosphorylation of ERK, JNK and p38 MAPKs in RAW 264.7 macrophages[1].
Licocoumarone (3-50 μM; 1 h pretreatment, followed by LPS stimulation for mRNA/24 h for protein) inhibits LPS-induced mRNA and protein expression of iNOS, IL-1β, IL-6 and IL-10 in a dose-dependent manner in RAW 264.7 macrophages, but does not affect the expression of TNF-α[1].
Licocoumarone (0-400 μM; 48 h) potently inhibits the viability of human pancreatic adenocarcinoma BxPC-3 cells, with an IC50 of 50.77 μM after 48 h of treatment[2].
Licocoumarone (25-50 μM; 2 h) significantly inhibits the proliferation of human pancreatic adenocarcinoma BxPC-3 cells, reducing the proportion of Edu-positive cells to 35.92% and 29.90%, respectively[2].
Licocoumarone (25-50 μM; initial treatment for 48 h; 7-14 day growth period) significantly reduces the colony-forming ability of human pancreatic adenocarcinoma BxPC-3 cells[2].
Licocoumarone (50 μM) significantly reduces the expression level of c-MET protein in human pancreatic adenocarcinoma BxPC-3 cells by inhibiting DYRK1A[2].
Licocoumarone (25-50 μM; 48 h) significantly inhibits the migration of human pancreatic adenocarcinoma BxPC-3 cells; it induces apoptosis in human pancreatic adenocarcinoma BxPC-3 cells, with dose-dependent apoptotic morphological changes (chromatin condensation, nuclear fragmentation) observed[2].
Licocoumarone (compound 18) (0.1-1000 μM) reversibly inhibits the neuraminidase in a non-competitive manner, with an IC50 of 27.8 μM and a Ki of 12.1 μM[3].
Licocoumarone (compound 13) selectively inhibits the growth of Bacillus cereus ATCC 11778 and Listeria monocytogenes ATCC 15313 with an MIC of 50 μM; it inhibits Candida parapsilosis ATCC 22019 with an MIC of 100 μM; and at concentrations up to 100 μM, it shows no activity against the tested Gram-negative bacteria, Staphylococcus aureus ATCC 25923, Candida albicans ATCC 10231 or Candida glabrata ATCC 90030[4].
Licocoumarone (25-50 μM; 24-48 h) exhibits weak, concentration- and biofilm age-dependent activity against preformed Listeria monocytogenes ATCC 15313 biofilms: the maximum eradication rate reaches approximately 45% against 24 h preformed biofilms at 50 μM, while no eradication activity is observed against 48 h preformed biofilms even at the highest concentration of 50 μM[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW 264.7 mouse macrophages
-
Concentration:1.5, 3, 6, 12, 24, 50, 100 μM
-
Incubation Time:24 h
-
Result:Did not reduce cell viability at concentrations up to 50 μM.
Maintained cell viability at 83.3% at 100 μM, showing minimal cytotoxicity.
-
Cell Line:LPS-stimulated RAW 264.7 mouse macrophages
-
Concentration:3, 12.5, 50 μM
-
Incubation Time:1 h pretreatment, followed by 30 min LPS stimulation
-
Result:Inhibited LPS-induced phosphorylation of ERK, JNK and p38 in a dose-dependent manner, with the strongest inhibition observed at 50 μM.
Repressed STAT3 phosphorylation solely at 50 μM without detectable activity at lower concentrations.
-
Cell Line:LPS-stimulated RAW 264.7 mouse macrophages
-
Concentration:3, 12.5, 50 μM
-
Incubation Time:1 h pretreatment, followed by LPS stimulation for mRNA
-
Result:Inhibited LPS-induced iNOS, IL-1β, IL-6, and IL-10 mRNA and protein expression in RAW 264.7 macrophages, but does not affect TNF-α expression.
-
Cell Line:human pancreatic adenocarcinoma BxPC-3 cells
-
Concentration:25, 50 μM
-
Incubation Time:2 h
-
Result:Reduced the percentage of Edu-positive proliferating cells from 53.86% to 35.92% and 29.90%, with decreased fluorescent spot number and intensity in treated groups.
-
Cell Line:human pancreatic adenocarcinoma BxPC-3 cells
-
Concentration:25, 50 μM
-
Incubation Time:48 h
-
Result:Reduced BxPC-3 cell migration into the denuded zone by approximately twofold and threefold.
-
Cell Line:human pancreatic adenocarcinoma BxPC-3 cells
-
Concentration:25, 50 μM
-
Incubation Time:48 h
-
Result:Increased the percentage of apoptotic (Annexin V-FITC/PI positive) cells from 1.10% (control) to 18.50% and 48.60%.
Chemical Information
-
CAS No. 118524-14-4
-
Molecular Weight 340.37
-
Formula C20H20O5
-
SMILES
OC1=CC(O)=C(C2=CC3=C(C=C(C(C/C=C(C)\C)=C3OC)O)O2)C=C1
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
Purity & Documentation
References
[2]. Zhao C, et al. Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A. Chemico-biological interactions. 2020 Jan 25;316:108913. [Content Brief]
[3]. Ryu YB, et al. Inhibition of neuraminidase activity by polyphenol compounds isolated from the roots of Glycyrrhiza uralensis. Bioorganic & medicinal chemistry letters. 2010 Feb 01;20(3):971-4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)